We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-21.46%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$111M
AUM Growth
+$2.27M
Cap. Flow
+$25.6M
Cap. Flow %
23.01%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$25.4M
2
LYEL icon
Lyell Immunopharma
LYEL
+$4.71M
3
PHVS icon
Pharvaris
PHVS
+$214K

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$4.79M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.28B
$69.2M 62.35%
4,410,581
+12,700
+0.3% +$214K
MAZE
2
Maze Therapeutics
MAZE
$1.49B
$23.3M 20.93%
+2,111,919
New +$25.4M
LYEL icon
3
Lyell Immunopharma
LYEL
$317M
$8.61M 7.75%
800,400
+384,150
+92% +$4.71M
KURA icon
4
Kura Oncology
KURA
$800M
$7.34M 6.61%
1,111,882
-615,000
-36% -$4.79M
RLAY icon
5
Relay Therapeutics
RLAY
$4.1B
$2.62M 2.36%
1,000,000
– –

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q1 2025 Portfolio in Review

As of Q1 2025, Foresite Capital Management IV held 5 positions worth $111M, up 2.1% from $109M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV deployed $25.6M of net new capital in Q1 2025, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Maze Therapeutics: 2,111,919 shares worth $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Kura Oncology, an estimated $4.79M trimmed.

  • Foresite Capital Management IV's largest Q1 2025 buy was Maze Therapeutics: 2,111,919 shares worth $23.3M.
  • Foresite Capital Management IV added most to Lyell Immunopharma in Q1 2025, an estimated $4.71M increase.
  • Foresite Capital Management IV's biggest Q1 2025 reduction was Kura Oncology, cutting an estimated $4.79M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $111M portfolio in Q1 2025.
  • Foresite Capital Management IV opened 1 new position and closed 0 in Q1 2025.
  • Foresite Capital Management IV's portfolio value rose 2.1% quarter-over-quarter to $111M.

Based on Foresite Capital Management IV's 13F filing for Q1 2025, filed 15 May 2025.